gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation

Therese Standal¹,³, Rachelle W Johnson¹, Narelle E McGregor³, Ingrid J Poulton¹, Patricia W M Ho¹, T John Martin¹,² and Natalie A Sims¹,²

¹St.Vincent’s Institute of Medical Research, 9 Princes St, Fitzroy, Victoria 3065, Australia
²Department of Medicine at St. Vincent’s Hospital Melbourne, The University of Melbourne, Fitzroy, Victoria, Australia
³Department of Cancer Research and Molecular Medicine, The KG Jebsen Center for Myeloma Research and Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway

Correspondence should be addressed to N A Sims
Email nsims@svi.edu.au

Abstract

Parathyroid hormone (PTH) treatment stimulates osteoblast differentiation and bone formation, and is the only currently approved anabolic therapy for osteoporosis. In cells of the osteoblast lineage, PTH also stimulates the expression of members of the interleukin 6 (IL-6) cytokine superfamily. Although the similarity of gene targets regulated by these cytokines and PTH suggest cooperative action, the dependence of PTH anabolic action on IL-6 cytokine signaling is unknown. To determine whether cytokine signaling in the osteocyte through glycoprotein 130 (gp130), the common IL-6 superfamily receptor subunit, is required for PTH anabolic action, male mice with conditional gp130 deletion in osteocytes (Dmp1Cre.gp130f/f) and littermate controls (Dmp1Cre.gp130w/w) were treated with hPTH(1–34) (30 μg/kg 5× per week for 5 weeks). PTH dramatically increased bone formation in Dmp1Cre.gp130w/w mice, as indicated by elevated osteoblast number, osteoid surface, mineralizing surface, and increased serum N-terminal propeptide of type 1 collagen (P1NP). However, in mice with Dmp1Cre-directed deletion of gp130, PTH treatment changed none of these parameters. Impaired PTH anabolic action was associated with a 50% reduction in Pth1r mRNA levels in Dmp1Cre.gp130f/f femora compared with Dmp1Cre.gp130w/w. Furthermore, lentiviral-Cre infection of gp130f/f primary osteoblasts also lowered Pth1r mRNA levels to 16% of that observed in infected C57/BL6 cells. In conclusion, osteocytic gp130 is required to maintain PTH1R expression in the osteoblast lineage, and for the stimulation of osteoblast differentiation that occurs in response to PTH.

Key Words
- glycoprotein-130 (gp130)
- osteoblast
- osteocyte
- osteoclast
- PTH
- PTH1R
- trabecular
- cortical
- bone formation

Introduction

Intermittent administration of parathyroid hormone (PTH) to animal models and humans (teriparatide (Forteo)) increases bone mass (Reeve et al. 1980, Neer et al. 2001, Lindsay et al. 2007), and is the only approved treatment for osteoporosis capable of inducing bone formation (reviewed in Hodsman et al. (2005) and Khosla et al. (2008)). However, the mechanisms by which intermittent PTH increases bone mass remain unclear, and identifying downstream targets of this pathway may aid in the design of improved anabolic therapies.
The effects of PTH on bone mass are likely to be mediated by cells of the osteoblast lineage. This lineage includes committed pre-osteoblasts, matrix-producing osteoblasts, bone lining cells, and matrix-embedded osteocytes. PTH acts directly at each stage of differentiation, as follows. PTH promotes pre-osteoblast differentiation (Dobnig & Turner 1995), inhibits osteoblast apoptosis (Jilka et al., 1999), and reactivates quiescent lining cells to become active osteoblasts (Kim et al., 2008, 2010). PTH also acts directly on osteocytes to reduce their expression of the WNT antagonist sclerostin, an inhibitor of bone formation (Bellido et al., 2005, Keller & Kneissel, 2005).

PTH also stimulates the expression of receptor activator of NF-kappa-B ligand (RANKL) by early osteoblast lineage cells, thereby promoting osteoclast differentiation (Udagawa et al., 1999). However, the stages of osteoblast differentiation most important for the actions of PTH remain controversial, because the expression of RANKL by matrix-embedded osteocytes is also stimulated by PTH (Xiong et al., 2011).

PTH also acts on the osteoblast lineage to rapidly promote the transcription of interleukin 6 (IL-6) family cytokines and receptors. These include Il6 (Greenfield et al., 1996), Il11, oncostatin M receptor (Osmr), leukemia inhibitory factor (Lif), and cytokine receptor-like factor 1 (Crlf1) (Walker et al., 2012). These cytokines all depend on the promiscuous co-receptor glycoprotein 130 (gp130) for signaling (reviewed in Sims & Walsh, 2010), and gp130 expression by the osteoblast lineage is also stimulated by PTH (Romas et al., 1996).

Many of the actions and gene targets of IL-6 family cytokines are common to those of PTH. As is the case with PTH, the cytokines IL-6, IL-11, OSM, LIF, and cardiotoxin (CT-1) promote osteoblast differentiation in vitro (Walker et al., 2008, 2010) and OSM, LIF, and CT-1 stimulate bone formation in vivo (Cornish et al., 1993, Walker et al., 2008, 2010). The family members IL-11, LIF, OSM, CT-1, and CNTF also inhibit osteocytic sclerostin expression (Walker et al., 2010, Johnson et al., 2014a). In addition, IL-6, IL-11, OSM, LIF, and CT-1, stimulate osteoblast lineage expression of RANKL (O’Brien et al., 1999, Palmqvist et al., 2002, Walker et al., 2008) and promote osteoclastogenesis when precursors are co-cultured with osteoblasts in vitro (Tamura et al., 1993, Richards et al., 2000). These similar effects and the upregulation of IL-6 family cytokines in osteoblasts by PTH suggest that this cytokine family may play a role in the actions of PTH on the osteoblast lineage.

Hence, in this study we examined the requirement of gp130 signaling in osteocytes for the anabolic action of PTH, using mice with Dmp1Cre-directed deletion of gp130 in osteocytes (Dmp1Cre,gp130f/f; Johnson et al., 2014b) and mature osteoblasts (Xiong et al., 2011, Torreggianii et al., 2013). We found that gp130 in these cells is required for PTH to increase osteoblast number and bone forming surfaces, and to maintain PTH1R expression in the osteoblast lineage.

**Materials and methods**

**Mice**

All animal procedures were conducted with the approval of the St. Vincent’s Health Melbourne Animal Ethics Committee. Dmp1Cre mice were obtained from Lynda Bonewald (University of Kansas, Kansas City, MO, USA; Lu et al., 2007). Floxed gp130 mice backcrossed onto C57/BL6 were obtained from Rodger McEver (Oklahoma Medical Research Foundation, Oklahoma City, OK, USA; Betz et al., 1998). Mice hemizygous for the Cre transgene were crossed with the gp130 flox mouse in which the transmembrane domain (exon 15) was flanked by loxP sites, resulting in ablation of intracellular gp130 signaling, as previously reported (Betz et al., 1998) and confirmed at the mRNA level in bone (Johnson et al., 2014b). For all experiments, Dmp1.Cre+ cousins were used as controls.

Six-week-old male Dmp1.Cre,gp130<sup>w/w</sup> or floxed Dmp1.Cre,gp130<sup>f/f</sup> mice were injected i.p. with 30 μg/kg human PTH 1–34 (hPTH 1–34) or vehicle, 5 days a week for 5 weeks (n=9/10 per group). This dose and duration of PTH treatment were chosen because it provides a robust increase in lamellar bone formation rate and osteoblast surface in male mice without increasing osteoclastogenesis (Walker et al., 2012, Takayar et al., 2013, Tonna et al., 2014). The mice were also injected with calcein (20 mg/kg) 7 and 2 days before tissue collection. The bones were collected 1 h after the last PTH injection. The mice were fasted for 12 h before anaesthesia with ketamine/xylazine and a final blood sample was collected by cardiac puncture. The blood samples were centrifuged for 10 min at 4000 x g and the serum was collected in a fresh tube and stored at –80 °C until analysis for cross-linked C-terminal telopeptide of type 1 collagen (CTX1), N-terminal propeptide of type 1 collagen (PINP) (Immunodiagnostics Systems Limited, Boldon, Tyne and Wear, UK), and PTH (Immunotopics, San Clemente, CA, USA) as per manufacturer’s instructions. One femur was flushed of marrow and the bone shaft was collected for RNA analyses as described previously (Walker et al., 2012). Briefly, bones were homogenized with a LS-10-35 Polytron homogenizer in
TRI for 4 × 5 s bursts and stored at −80 °C. RNA from each bone was purified using the RNasy lipid tissue minikit (Qiagen), according to manufacturer’s instructions.

The other femur was analyzed by micro-computed tomography as described previously (Johnson et al. 2014b) using the SkyScan 1076 System (Bruker-microCT, Kontich, Belgium). The images were acquired using the following settings: 9 μm voxel resolution, 0.5 mm aluminium filter, 48 kV voltage, and 100 μA current, exposure time, rotation 0.5°, frame averaging = 1. The images were reconstructed and analyzed using SkyScan Software programs NRecon (version 1.6.3.3), DataViewer (version 1.4.4), and CT Analyser (version 1.12.0.0). Femoral trabecular analysis region of interest (ROI) was determined by identifying the distal end of the femur and calculating 15% of the total femur length toward the femora mid-shaft, where we then analyzed an ROI of 12.6% of the total femur length. The analysis of bone structure was completed using adaptive thresholding (mean of min and max values) in CT Analyser. The thresholds for analysis were determined based on multilevel Otsu thresholding of the entire data set, and were set at 45–255 for trabecular bone. The cortical analyses were performed at 35% above the distal end of the femur toward the femora mid-shaft, also with a 12.6% ROI with the threshold values set at 100–255.

Tibiae were collected for histomorphometric analyses as previously described (Sims et al. 2006). Briefly, trabecular histomorphometry was carried out on undecalcified sections in the secondary spongiosa of the proximal tibia, in a region 370 μm below the proximal edge of the hypertrophic zone of the growth plate, extending 1.11 mm in the proximal direction. Periosteal histomorphometry was carried out on the antero-fibular side of the tibia, commencing 1.11 mm below the chondro-osseus junction of the growth plate, and extending 1.11 mm in the proximal direction. The nomenclature is as described previously (Parfitt et al. 1987).

**Lenti-Cre viral infection**

Calvarial osteoblasts were collected from C57/BL6 WT and gp130f/f neonates by digesting calvaria in 1:2 collagenase II/dispose solution at 37 °C on a shaker (1 × 5 min 4 × 10 min digestions). The cells were resuspended in culture media (alpha-MEM + 10% fetal bovine serum), and allowed to adhere overnight before being frozen and stored in liquid nitrogen. When required, isolated cells were thawed and expanded in culture and infected with a GFP-tagged lenti-Cre virus synthesized as described previously (Tonna et al. 2014) for 24 h with polybrene in the maintenance media. Following infection, media was changed and cells were evaluated for GFP expression by microscopy; > 30–60% transfection efficiency was observed (n = 3 independent experiments). The cells were expanded in culture for 2–3 weeks in alpha-MEM + 10% fetal bovine serum, and GFP positive cells (fluorescence driven by Cre transgene expression) were sorted on a FACS Aria (BD Biosciences, San Jose, CA, USA) for GFP. The GFP + cells were harvested for RNA in trizol (Life Technologies) and separated and precipitated using chloroform and isopropanol. Extracted RNA was treated with DNase using Ambion TURBO DNA-free Kit (Life Technologies) and quantified on a NanoDrop ND1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA).

**Semi-quantitative real-time PCR**

cDNA synthesis from 50 to 100 ng DNase-treated RNA from each femur or cell culture preparation was carried out using AffinityScript (Agilent Technologies, Santa Clara, CA, USA) as per the manufacturer’s instructions. The stock cDNA was diluted to a concentration of 5 ng/μl and semi-quantitative real-time PCR (qPCR) was performed on 12.5 ng cDNA in a reaction volume of 10 μl using in-house master mix of 10× AmpliTaq Gold with SYBR Green nucleic acid gel stain (Life Technologies). Dkk1 primers were designed using NCBI Primer Blast: forward, GAG-GGGGAAATTGAGGAAAGC and reverse, ACGGAGC-CTTCTTGCTTCTT. Other primers were as previously described for PthIr, hypoxanthine phosphoribosyltransferase 1 (Hprt1), Sost, Tnfsf11, Il6 (Allan et al. 2008), β-2 microglobulin (B2m) (McGregor et al. 2010), and hydroxymethylbilane synthase (Hmbs) (Johnson et al. 2014b).

The samples were dispensed onto optically clear 96-well plates (Thermo Scientific) and run on a Stratagene Mx3000P (Agilent Technologies). The cycling conditions were 95 °C for 10 min (95 °C for 30 s, 58 °C for 1 min, and 72 °C for 30 s) × 40 cycles, followed by a dissociation step (95 °C for 1 min, 55 °C for 30 s, and 95 °C for 30 s). The post-run samples were analyzed using MxPro (Agilent Technologies, Santa Clara, CA, USA) and reported using linear ΔCT values normalized to the geometric mean of the two housekeeping genes (HKG) Hprt1 and Hmbs or to B2m as indicated.

**Statistical analysis**

All graphs are presented as the mean/genotype ± S.E.M. N = 5–10 animals/group as indicated in the figure legend. For in vitro experiments, data shown is the average of three
Results

Dmp1Cre.gp130<sup>f/f</sup> mice show no increase in the number of trabecular osteoblasts in response to PTH

PTH treatment at 30 µg/kg per day significantly increased osteoblast number/bone perimeter (NOb/BPm) on trabecular bone in Dmp1Cre.gp130<sup>w/w</sup> mice by 76% (Fig. 1A). Osteoblast surface/bone surface (Obs/BS; Fig. 1B) and osteoid surface/bone surface (OS/BS; Fig. 1C) were also elevated by PTH treatment to similar extents. We detected no significant changes in osteoid thickness in Dmp1Cre.gp130<sup>w/w</sup> mice after PTH treatment (Fig. 1D).

In contrast to Dmp1Cre.gp130<sup>w/w</sup> mice, PTH treatment did not increase osteoblast or osteoid-derived parameters in age- and sex-matched Dmp1Cre.gp130<sup>f/f</sup> mice (Fig. 1A, B, C and D). Two-way ANOVA revealed that the effects of PTH treatment on both NOB/BPm and Obs/BS were significantly reduced in the Dmp1Cre.gp130<sup>f/f</sup> mice compared with Dmp1Cre.gp130<sup>w/w</sup> controls (interaction P=0.039 and P=0.043 respectively). This indicates that the effect of PTH on osteoblast differentiation is dependent on gp130 expression in osteocytes.

In line with the effects on osteoblast numbers, bone forming surfaces, indicated by incorporation of calcine labels, including both double-labeled surface (dLS/BS) (Fig. 1E) and single-labeled surface (P<0.05, not shown) were significantly greater in PTH-treated Dmp1Cre.gp130<sup>w/w</sup> mice compared with controls. Again, this was not observed in Dmp1Cre.gp130<sup>f/f</sup> mice. Mineral apposition rate (MAR) was significantly greater in both Dmp1Cre.gp130<sup>f/f</sup> and Dmp1Cre.gp130<sup>w/w</sup> mice treated with PTH compared with their vehicle-treated controls (Fig. 1F), indicating that an increase in mineralization rate in response to PTH is retained on those surfaces on which bone formation occurs in Dmp1Cre.gp130<sup>f/f</sup> mice.

PTH-treated Dmp1Cre.gp130<sup>w/w</sup> mice had significantly higher serum P1NP levels than Dmp1Cre.gp130<sup>w/w</sup> untreated controls. In contrast, in Dmp1Cre.gp130<sup>f/f</sup> mice there was no significant effect of PTH on P1NP levels compared with vehicle-treated Dmp1Cre.gp130<sup>f/f</sup> mice (Fig. 1G); interaction P value = 0.009 by two-way ANOVA. These results are consistent with the histomorphometry data and confirm that at a systemic level, the effect of PTH on bone formation is blunted in Dmp1Cre.gp130<sup>f/f</sup> mice.

In both Dmp1Cre.gp130<sup>f/f</sup> and Dmp1Cre.gp130<sup>w/w</sup> mice, intermittent human PTH treatment led to reduced production of endogenous circulating murine PTH levels (Fig. 1H), demonstrating that negative feedback at the parathyroid gland induced by exogenous PTH administration was maintained in both groups of mice.
Although this dose of PTH significantly increased all markers of bone formation in Dmp1Cre.gp130<sup>W/w</sup> mice, we did not detect a significant increase in trabecular bone mass of these mice, previously reported (Johnson et al. 2014b), was confirmed.

**Table 1** Effects of PTH on trabecular and cortical bone in femora from Dmp1Cre.gp130<sup>W/w</sup> and Dmp1Cre.gp130<sup>F/f</sup> mice.

<table>
<thead>
<tr>
<th></th>
<th>Dmp1Cre.gp130&lt;sup&gt;W/w&lt;/sup&gt;</th>
<th>Dmp1Cre.gp130&lt;sup&gt;F/f&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vehicle (n=9)</td>
<td>PTH (n=10)</td>
</tr>
<tr>
<td>BV/TV (%)</td>
<td>24.86 ± 0.42</td>
<td>21.54 ± 1.32</td>
</tr>
<tr>
<td>Tb.Th (μm)</td>
<td>57.61 ± 1.80</td>
<td>56.49 ± 2.22</td>
</tr>
<tr>
<td>Tb.N (/mm)</td>
<td>4.35 ± 0.15</td>
<td>3.80 ± 0.16</td>
</tr>
<tr>
<td>Tb.Sp (μm)</td>
<td>122.71 ± 2.96</td>
<td>144.39 ± 14.04</td>
</tr>
<tr>
<td>Ct.Ar (mm&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>0.60 ± 0.02</td>
<td>0.65 ± 0.02</td>
</tr>
</tbody>
</table>

Fixed nondemineralized femora from vehicle- or PTH-treated mice were analyzed by μCT. Effect of gp130<sup>F/f</sup> transgene: **++** P < 0.001 vs Dmp1Cre.gp130<sup>W/w</sup> (two-way ANOVA with Sidak multiple comparisons test). BV/TV, bone volume per total volume of the region of interest; Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation; Ct.Ar, cortical area.

No effect of intermittent PTH treatment on bone resorption

This protocol of intermittent PTH treatment did not significantly change osteoclast number/bone perimeter (NOc/BPm) (Fig. 2A), osteoclast number/osteoclast perimeter (Fig. 2B), osteoclast surface/bone surface (OCS/BS) (Fig. 2C), or serum levels of cross-linked CTX1 (Fig. 2D) in either Dmp1Cre.gp130<sup>F/f</sup> or Dmp1Cre.gp130<sup>W/w</sup> mice. This confirms our previous observations using similar protocols over 4 weeks of treatment (Walker et al. 2012, Takyar et al. 2013, Tonna et al. 2014).

**Figure 2**
No effect of intermittent PTH on bone resorption. Male mice were treated with hPTH (1–34) at 30 μg/kg per day for 5 weeks. (A) Numbers of osteoclasts per unit bone perimeter (NOc/BPm), (B) numbers of osteoclasts per unit osteoclast perimeter (NOc/OcPm), (C) osteoclast surface per unit bone surface (Ocs/BS) measured in the proximal tibial secondary spongiosa, and (D) serum levels of cross-linked C-terminal telopeptide of type 1 collagen (CTX1) in PTH and vehicle-treated Dmp1Cre.gp130<sup>W/w</sup> (gp130 w/w) and Dmp1Cre.gp130<sup>F/f</sup> (gp130 f/f) mice. Scale bars are mean ± I.E.M., n = 8–10 per group.

**Effects of PTH on cortical bone**

Periosteal MAR (Fig. 3A), periosteal mineralising surface (Fig. 3B) and periosteal perimeter (Fig. 3C) were all significantly greater in PTH-treated Dmp1Cre.gp130<sup>W/w</sup> mice compared with untreated mice. None of these parameters were significantly increased by PTH treatment in Dmp1Cre.gp130<sup>F/f</sup> mice compared with genotype-matched vehicle controls (Fig. 3A–C), indicating that periosteal growth in response to PTH may also be impaired in the absence of osteocytic gp130.

Normal response of osteoclastic genes, but lack of inhibition of WNT signaling inhibitors by PTH treatment in Dmp1Cre.gp130<sup>F/f</sup> mice

RANKL (gene name Tnfsf11) and IL-6 (Il6) are both potent stimuli of osteoclast formation, and PTH increases their expression in cells of the osteoblast lineage (Greenfield et al. 1995, Udagawa et al. 1999). Indeed, in marrow-flushed femoral samples collected 1 h after the last of these 5 weeks of injections, mRNA levels of Tnfsf11 and Il6 were significantly higher in both genotypes after PTH treatment (Fig. 4A and B); this increase was not significantly affected by the genotype (two-way ANOVA interaction P = 0.365 and 0.314 respectively). This indicated that among cells in the flushed femora, which would include osteoblasts at different stages of differentiation as well as osteocytes, are some cells that retain normal responses of these genes to PTH.

Wingless (WNT)-signaling is important for osteoblast differentiation and bone formation, and PTH has been shown to stimulate WNT signaling by suppressing Dickopf1 (Dkk1) and sclerostin (Sost) expression in the
were significantly lower in PTH-treated Sost mRNA levels (Fig. 4D). These differences in the effects of PTH treatment on gene expression were significant by two-way ANOVA for both Dkk1 (interaction \( P = 0.01 \)) and Sost (interaction \( P = 0.003 \)). Thus, PTH treatment does not decrease WNT antagonist expression in Dmp1Cre.gp130f/f mice, implying that gp130 signaling in osteocytes is important for the PTH effect on WNT signaling inhibitors.

**Pth1r expression is reduced in DMP1Cre.gp130f/f and gp130-deficient osteoblasts**

Since many effects of PTH were blocked in Dmp1Cre.gp130f/f mice, we quantified Pth1r mRNA levels in flushed femurs from untreated 12-week-old Dmp1Cre.gp130f/f and Dmp1Cre.gp130w/w mice. Surprisingly, Pth1r mRNA expression was 47% lower in Dmp1Cre.gp130f/f compared with Dmp1Cre.gp130w/w femurs (\( P = 0.03; \) Fig. 5A).

These findings were supported by in vitro data, where C57/BL6 and gp130f/f calvarial osteoblasts were infected with lentiviral Cre-recombinase. In Cre-infected gp130f/f osteoblasts, gp130 was significantly lowered by 52%, and Pth1r mRNA was 84% lower than in infected C57/BL6 cells of osteoblast lineage (Keller & Kneissel 2005, Yao et al. 2011). For this reason, we quantified mRNA levels of Dkk1 and Sost in flushed femurs. As expected, Dkk1 mRNA levels were significantly lower in PTH-treated Dmp1Cre.gp130w/w femurs compared with untreated mice. However, Dkk1 was not lower in femurs from PTH-treated Dmp1Cre.gp130f/f mice compared with controls (Fig. 4C). Sost mRNA levels were slightly, but not significantly, lowered in response to PTH in Dmp1Cre.gp130w/w femora. Dmp1Cre.gp130f/f femora showed a lower level of Sost mRNA compared with vehicle-treated Dmp1Cre.gp130w/w controls; with PTH treatment these mice showed a significant increase in Sost mRNA levels (Fig. 4D). These effects of PTH treatment on gene expression were significant by two-way ANOVA for both Dkk1 (interaction \( P = 0.01 \)) and Sost (interaction \( P = 0.003 \)). Thus, PTH treatment does not decrease WNT antagonist expression in Dmp1Cre.gp130f/f mice, implying that gp130 signaling in osteocytes is important for the PTH effect on WNT signaling inhibitors.
**Discussion**

This work demonstrates that PTH-induced osteoblast differentiation is dependent on gp130 expression in mature osteoblast lineage cells. gp130 is needed to maintain Pth1r expression in osteoblasts, and is required for PTH to suppress the WNT-antagonists Dkk1 and Sost. In contrast, gp130 expression by osteocytes is not required for PTH to stimulate mRNA levels of the pro-osteoclastogenic factors RANKL (Tnfsf11) and Il6 in bone.

The stimulatory effect of PTH on trabecular osteoblast numbers and mineralizing surface was completely ablated in *Dmp1Cre.gp130⁺/⁻* mice. This may, at least partly, be explained by the lack of a reduction in both WNT signaling inhibitors Sost and Dkk1 in response to PTH. WNT signaling stimulates osteoblast differentiation, and it has been postulated that this is one pathway through which PTH stimulates bone formation (Kulkarni et al. 2005), a hypothesis supported by impaired PTH responses in mice overexpressing sclerostin or Dkk1 (Guo et al. 2010, Kramer et al. 2010). PTH directly inhibits Sost via cAMP–PKA signaling (Keller & Kneissl 2005). The IL-6 family cytokines also rapidly inhibit Sost, although the mechanism remains unknown (Walker et al. 2010). Whether the reduction in the effect of PTH on WNT signaling is entirely due to the reduced PTH1R expression or results from some dependence on gp130 cytokines by this same pathway in osteoblasts and osteocytes remains unclear.

In contrast to the effect on WNT-antagonists, both *Dmp1Cre.gp130⁺/⁺* and *Dmp1Cre.gp130⁺/⁻* mice demonstrated increased femoral *Tnfsf11* and *Il6* mRNA levels in response to PTH. Despite these increases in both genotypes, osteoblast numbers were unchanged, as we have previously reported with this low dose of intermittent PTH treatment (Takyar et al. 2013, Tomna et al. 2014), likely because the inductions of Tnfsf11 and Il6 are transient (Ma et al. 2001, Walker et al. 2012). IL-6 and RANKL are expressed by a wide range of cells in the bone, including osteoblast lineage cells as well as osteocytes (Lee & Lorenzo 1999, Dai et al. 2006, Nakashima et al. 2011, Xiong et al. 2012). IL-6 and RANKL are expressed by a wide range of cells in the bone, including osteoblast lineage cells as well as osteocytes (Lee & Lorenzo 1999, Dai et al. 2006, Nakashima et al. 2011, Xiong et al. 2012). Although PTH has recently been suggested to directly promote RANKL expression in osteocytes (Xiong et al. 2011), our findings suggest that the major cellular targets that produce these pro-osteoclastogenic factors in response to PTH are not osteocytes. Notably, although PTH was unable to increase osteoblast numbers or mineralizing surface in the *Dmp1Cre.gp130⁺/⁻* mice, on those surfaces where double calcein labels were incorporated into the bone matrix, the distance between them (MAR) was significantly greater in PTH-treated mice, regardless of genotype. This suggests that bone-forming osteoblasts in *Dmp1Cre.gp130⁺/⁻* mice retain sufficient PTHR expression to respond to PTH with increased matrix production. Since marrow was flushed from the femora, and Pth1r levels were dramatically reduced in undifferentiated cultured Cre-expressing cells, we suggest that the...
key PTH-responsive cells producing RANKL and IL-6 in this model are less differentiated osteoblasts, not expressing Dmp1Cre, on the bone surface.

**Pth1r** mRNA was lower in cortical bone of *Dmp1Cre,gp130f/f* mice, in comparison with littermate controls, an effect that was reproduced when gp130 was deleted in cultured primary calvarial osteoblasts. There are two ways to understand this: firstly, as osteoblast differentiation is impaired in the *Dmp1Cre,gp130f/f* mice (Johnson et al. 2014b) and PTH1R expression in the osteoblast lineage is higher in more mature osteoblasts (Allan et al. 2003, 2008, Balic et al. 2010), there may be fewer mature PTH1R-expressing osteoblasts present within the bone of these mice. Another interpretation is that gp130 is needed to maintain the expression of PTH1R in the osteoblast lineage. This latter hypothesis is supported by our *in vitro* data, as we observed that a reduction in gp130 by about 50% in calvarial osteoblasts cultured *in vitro* reduced *Pth1r* mRNA levels by nearly 80%. This further suggests that, as well as maintaining PTH1R levels in the osteocyte, gp130 may maintain PTH1R expression throughout the osteoblast lineage.

Although *Pth1r* levels were low in the femora of *Dmp1Cre,gp130f/f* mice, their phenotype is strikingly different to mice with a conditional deletion of *Pth1r* in osteocytes (Ocy-PPRKO), generated using the same *Dmp1Cre* (Saini et al. 2013). Ocy-PPRKO mice showed a greater trabecular bone mass than controls, with no significant alteration in osteoblast numbers, indicating that the underlying cause of bone fragility in the *Dmp1Cre,gp130f/f* mice is not simply low PTH1R expression in the osteocyte. As observed in *Dmp1Cre,gp130f/f* mice, Ocy-PPRKO mice failed to reduce *Sost* in response to PTH treatment. However, in direct contrast to *Dmp1Cre,gp130f/f* mice, Ocy-PPRKO mice lacked a *Tnfsf11* in response to PTH. This suggests that the *Dkk1/Sost* and *Tnfsf11/Ile6st* responses to PTH occur in different cell populations, and it is only the former that is affected by *Dmp1Cre*-mediated gp130 deletion. Alternatively, the *Dkk1/Sost* induction may require a higher level of PTH1R expression than the *Tnfsf11/Ile6st* response; the low level of PTH1R expression in the *Dmp1Cre,gp130f/f* mice may be sufficient for the latter.

In addition to mediating the response of osteoblasts to exogenous PTH treatment, PTH1R also acts as a receptor for PTH-related protein (PTHrP). Although first identified as the mediator of humoral hypercalcemia of malignancy (Suva et al. 1987), PTHrP is also produced by the osteoblast lineage (Kartsogiannis et al. 1997). This local PTHrP production is essential for normal osteoblast differentiation, as indicated by studies of an osteoblast-lineage PTHrP-null mouse (Miao et al. 2005). This suggests that basal defects in osteoblast differentiation in our model lacking gp130 in osteocytes may relate specifically to a lack of PTHrP signal. Notably, and in direct contrast to our model, the osteoblast-lineage knockout of PTHrP also exhibited a significant impairment in osteoclastogenesis (Miao et al. 2005), a finding that may relate to the difference in the gene-driving expression of the Cre-recombinase. The *Pthrp* deletion was driven by the *Col2.3Cre*, which would delete expression in osteocytes, but also in less mature osteoblasts than the *Dmp1Cre* that we have used. Again, this suggests that the PTH-induced expression of RANKL is likely to occur in less mature osteoblasts.

In conclusion, in addition to the recently described role of osteocytic gp130 in maintaining bone formation and strength (Johnson et al. 2014b), the current study has revealed a new role for gp130 in the osteoblast lineage in bone: it is needed to maintain PTH1R expression and to increase osteoblast numbers in response to anabolic PTH treatment.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by a National Health and Medical Research Council (Australia) Project Grant 1002728. N A S is supported by a National Health and Medical Research Council (Australia) Senior Research Fellowship. T S is supported by a Senior Research Fellowship from the Norwegian Cancer Society (project number 538153). The Victorian State Government Operational Infrastructure Support Scheme provides support to St. Vincent’s Institute of Medical Research.

Author contributions

Acknowledgements
The authors thank Joshua Johnson for technical expertise in the processing of bone samples for histomorphometric analysis, Dr Stephen Tonna for advice on Lentiviral Cre infection, and Dr Nicole Walsh for design of the Dkk1 primers.
References


Dai JC, He P, Chen X & Greenfield EM 2006 TNFα and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone 38 509–520. (doi:10.1016/j.bone.2005.10.007)

Dobign H & Turner RT 1995 Evidence that intermittent treatment with inhibitory factor on bone


Johnson RW, White JD, Walker EC, Martin TJ & Sims NA 2014a Myokines (muscle-derived cytokines and chemokines) including cilary neurotrophic factor (CNTF) inhibit osteoblast differentiation. Bone 64C 47–56. (doi:10.1016/j.bone.2014.03.053)


Lee SK & Lorenzo JA 1999 Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteolast-like cell formation. Endocrinology 140 3552–3561. (doi:10.1210/endo.140.8.6887)


Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonevald LF, Kodama T, Wutz A, Wagner EF et al. 2011 Evidence for...


Palmqvist P, Persson E, Conaway HH & Lerner UH 2002 IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvariae. Journal of Immunology 169 3353–3362. (doi:10.4049/jimmunol.69.6.3353)


Torreggiani E, Matthews BG, Pelja S, Matic I, Horowitz MC, Grecvic D & Kalajzic I 2013 Preosteocytes/osteocytes have the potential to dedifferentiate becoming a source of osteoblasts. PLoS ONE 8 e75204. (doi:10.1371/journal.pone.0075204)


Received in final form 19 August 2014
Accepted 15 September 2014
Accepted Preprint published online 16 September 2014

http://joe.endocrinology-journals.org
DOI: 10.1538/JOE-14-0424
© 2014 Society for Endocrinology
Printed in Great Britain